FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126579487> ?p ?o ?g. }

• W3126579487 endingPage "184" @default.
• W3126579487 startingPage "173" @default.
• W3126579487 abstract "Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease‐modifying antirheumatic drugs (bDMARDs) within the United States (US) Corrona RA registry. Methods IRs (number of first events/100 patient‐years) of major adverse cardiovascular events (MACE), serious infection events (SIEs), herpes zoster (HZ), malignancies, and death were estimated among tofacitinib and bDMARD initiators, regardless of dose/schedule, between November 6, 2012 (US Food and Drug Administration tofacitinib approval), and July 31, 2018 (follow‐up through January 31, 2019). Propensity score (PS) methods were used to control for nonrandom prescribing practices. Hazard ratios (HRs) were calculated to compare rates using multivariable‐adjusted Cox regression. Different risk windows were used for acute (MACE, SIEs, HZ, and venous thromboembolic events [VTEs]) and long‐term (malignancy and death) events. VTEs were assessed descriptively. Results For MACE, SIEs, and HZ, 1999 (3152.1 patient‐years) and 8358 (12 869.4 years) tofacitinib and bDMARD initiators were included, respectively; for malignancy/death, 1999 (4505.6 patient‐years) and 6354 (16 670.8 patient‐years) initiators were included, respectively. AE rates were similar across cohorts, except for HZ, which was significantly higher with tofacitinib versus bDMARDs (PS‐trimmed adjusted HR 2.32; 95% confidence interval [CI] 1.43‐3.75). There were 45 (zero serious) and 88 (five serious) HZ events with tofacitinib and bDMARDs, respectively. Sensitivity analyses demonstrated similar results. VTE IRs (95% CI) were 0.29 (0.13‐0.54) and 0.33 (0.24‐0.45) for tofacitinib and bDMARDs, respectively. Conclusion In this registry analysis, both cohorts had similar MACE, SIE, malignancy, death, and VTE rates; HZ rates were higher for tofacitinib initaitors than for bDMARD initiators." @default.
• W3126579487 created "2021-02-15" @default.
• W3126579487 creator A5006565253 @default.
• W3126579487 creator A5010819140 @default.
• W3126579487 creator A5014147030 @default.
• W3126579487 creator A5021670415 @default.
• W3126579487 creator A5030754645 @default.
• W3126579487 creator A5030768494 @default.
• W3126579487 creator A5032298796 @default.
• W3126579487 creator A5036748733 @default.
• W3126579487 creator A5038132563 @default.
• W3126579487 creator A5044555927 @default.
• W3126579487 creator A5047193011 @default.
• W3126579487 creator A5049960008 @default.
• W3126579487 creator A5058110978 @default.
• W3126579487 creator A5063641495 @default.
• W3126579487 creator A5064025296 @default.
• W3126579487 date "2021-02-11" @default.
• W3126579487 modified "2023-10-14" @default.
• W3126579487 title "Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry" @default.
• W3126579487 cites W1974321634 @default.
• W3126579487 cites W1990105300 @default.
• W3126579487 cites W2014330392 @default.
• W3126579487 cites W2035320881 @default.
• W3126579487 cites W2038992287 @default.
• W3126579487 cites W2046744512 @default.
• W3126579487 cites W2062694326 @default.
• W3126579487 cites W2069302785 @default.
• W3126579487 cites W2078347589 @default.
• W3126579487 cites W2085947993 @default.
• W3126579487 cites W2101217991 @default.
• W3126579487 cites W2106799757 @default.
• W3126579487 cites W2117335168 @default.
• W3126579487 cites W2129948300 @default.
• W3126579487 cites W2133633410 @default.
• W3126579487 cites W2149447280 @default.
• W3126579487 cites W2153414586 @default.
• W3126579487 cites W2167939282 @default.
• W3126579487 cites W2265836205 @default.
• W3126579487 cites W2343866616 @default.
• W3126579487 cites W2416365354 @default.
• W3126579487 cites W2584430503 @default.
• W3126579487 cites W2626892937 @default.
• W3126579487 cites W2749941863 @default.
• W3126579487 cites W2755252346 @default.
• W3126579487 cites W2761295519 @default.
• W3126579487 cites W2782361381 @default.
• W3126579487 cites W2789471630 @default.
• W3126579487 cites W2912017753 @default.
• W3126579487 cites W2926455583 @default.
• W3126579487 cites W3000382576 @default.
• W3126579487 cites W4211111012 @default.
• W3126579487 doi "https://doi.org/10.1002/acr2.11232" @default.
• W3126579487 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7966883" @default.
• W3126579487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33570260" @default.
• W3126579487 hasPublicationYear "2021" @default.
• W3126579487 type Work @default.
• W3126579487 sameAs 3126579487 @default.
• W3126579487 citedByCount "69" @default.
• W3126579487 countsByYear W31265794872021 @default.
• W3126579487 countsByYear W31265794872022 @default.
• W3126579487 countsByYear W31265794872023 @default.
• W3126579487 crossrefType "journal-article" @default.
• W3126579487 hasAuthorship W3126579487A5006565253 @default.
• W3126579487 hasAuthorship W3126579487A5010819140 @default.
• W3126579487 hasAuthorship W3126579487A5014147030 @default.
• W3126579487 hasAuthorship W3126579487A5021670415 @default.
• W3126579487 hasAuthorship W3126579487A5030754645 @default.
• W3126579487 hasAuthorship W3126579487A5030768494 @default.
• W3126579487 hasAuthorship W3126579487A5032298796 @default.
• W3126579487 hasAuthorship W3126579487A5036748733 @default.
• W3126579487 hasAuthorship W3126579487A5038132563 @default.
• W3126579487 hasAuthorship W3126579487A5044555927 @default.
• W3126579487 hasAuthorship W3126579487A5047193011 @default.
• W3126579487 hasAuthorship W3126579487A5049960008 @default.
• W3126579487 hasAuthorship W3126579487A5058110978 @default.
• W3126579487 hasAuthorship W3126579487A5063641495 @default.
• W3126579487 hasAuthorship W3126579487A5064025296 @default.
• W3126579487 hasBestOaLocation W31265794871 @default.
• W3126579487 hasConcept C126322002 @default.
• W3126579487 hasConcept C141071460 @default.
• W3126579487 hasConcept C197934379 @default.
• W3126579487 hasConcept C207103383 @default.
• W3126579487 hasConcept C2776233030 @default.
• W3126579487 hasConcept C2777575956 @default.
• W3126579487 hasConcept C2778886723 @default.
• W3126579487 hasConcept C2780739214 @default.
• W3126579487 hasConcept C44249647 @default.
• W3126579487 hasConcept C45393284 @default.
• W3126579487 hasConcept C500558357 @default.
• W3126579487 hasConcept C71924100 @default.
• W3126579487 hasConceptScore W3126579487C126322002 @default.
• W3126579487 hasConceptScore W3126579487C141071460 @default.
• W3126579487 hasConceptScore W3126579487C197934379 @default.
• W3126579487 hasConceptScore W3126579487C207103383 @default.
• W3126579487 hasConceptScore W3126579487C2776233030 @default.
• W3126579487 hasConceptScore W3126579487C2777575956 @default.
• W3126579487 hasConceptScore W3126579487C2778886723 @default.

• next